Abstract
Seasonality plays an essential role in the dynamics of many infectious diseases. Its confirmation in an emerging infectious disease is usually done using time series data from several years. By using statistical regression methods for time-series data pooled from more than 50 countries from both hemispheres, we show how to determine its presence in a pandemic at the onset of the seasonal period. We measure its expected effect in the mean transmission rate of SARS-coV-2 and predict when further epidemic outbreaks of COVID-19 will occur. The obtained result in the Northern Hemisphere shows that seasonality reduced the mean growth rate in 222.5% in April 2020. A relative reduction greater than 100% should be interpreted as a reduction changing an increasing rate to a decreasing one. In contrast, at the same moment, the seasonal effect in the Southern Hemisphere increased the mean growth rate in 740.3%. Our analysis simultaneously considers other confounding factors to properly separate them from seasonal effects and, in addition, we measure the mean global effect of social-distancing interventions and its relation with income. Future COVID-19 waves are expected to occur in autumn/winter seasons, typically between September and March in the Northern Hemisphere, and between April and September in the Southern Hemisphere. Simulations of a seasonal SEIR model with a social distancing effect are shown to describe the behavior of COVID-19 outbreaks in several countries. These results provide vital information for policy makers to plan their actions against the new coronavirus disease, particularly in the optimization of social-distancing interventions and vaccination schedules. Ultimately, our methods can be used to identify and measure seasonal effects in a future pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed with public available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Many errors corrected. Some figures have been modified. Section with a compartmental model for COVID-19 pandemic included in the supplementary appendix.
Data Availability
All data used in this manuscript is public available.
